Brief: Tianjin Development Says Lisheng Pharmaceutical Subscribes To Investment Products Totaling RMB180 Million
25/06/2026 16:33
BRIEF-Tianjin Development Says Lisheng Pharmaceutical Subscribes To Investment Products Totaling RMB180 Million June 25 (Reuters) - Tianjin Development Holdings Ltd 0882.HK:
LISHENG PHARMACEUTICAL SUBSCRIBES TO INVESTMENT PRODUCTS TOTALING RMB180 MILLION ON JUNE 25, 2026
Further company coverage: 0882.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tianjin Development Holdings
See all newsHong Kong's Tianjin Development HY revenue on lower pharmaceutical, utilities sales
Brief: Tianjin Development Says Teng Fei Resigns As Chairman And Executive Director
Brief: Tianjin Development Says H1 2026 Net Profit Seen At RMB 73-83 Million For Tianjin Lisheng Pharmaceutical
Brief: Tianjin Development Says Lisheng Pharmaceutical Subscribes To Investment Products Totaling RMB180 Million
Brief: Tianjin Development Says Tianjin Lisheng Pharmaceutical QTRLY Operating Income RMB 332.28 Mln